About Us

Renown Pharma is obtaining regulatory approval for a patented sublingual formulation of apomorphine for the treatment of severe uncontrollable motor fluctuations in late-stage Parkinson's disease.

​

As apomorphine is considered to be the "gold standard" treatment to turn late-stage Parkinson's disease patients suffering from "OFF" episodes back "ON" and is currently only available as either a subcutaneous injection or via infusion, Renown has developed a simple, patented dual chamber device. With pH3 stabilised apomorphine in one chamber and a neutralizing agent and absorption enhancer in the other, Renown's device delivers the medication under the tongue, where the two liquids are combined to create a pH7 neutral liquid which is absorbed via the buccal mucosa.